Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Change in Cash: 2013-2024

Historic Change in Cash for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Dec 2024 value amounting to -$3.2 million.

  • Viridian Therapeutics, Inc.\DE's Change in Cash fell 43.53% to $52.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$30.7 million, marking a year-over-year decrease of 134.57%. This contributed to the annual value of -$3.2 million for FY2024, which is 93.87% up from last year.
  • According to the latest figures from FY2024, Viridian Therapeutics, Inc.\DE's Change in Cash is -$3.2 million, which was up 93.87% from -$52.8 million recorded in FY2023.
  • Viridian Therapeutics, Inc.\DE's 5-year Change in Cash high stood at $113.3 million for FY2022, and its period low was -$52.8 million during FY2023.
  • Moreover, its 3-year median value for Change in Cash was -$3.2 million (2024), whereas its average is $19.1 million.
  • Per our database at Business Quant, Viridian Therapeutics, Inc.\DE's Change in Cash soared by 3,248.42% in 2022 and then plummeted by 146.57% in 2023.
  • Viridian Therapeutics, Inc.\DE's Change in Cash (Yearly) stood at $21.1 million in 2020, then plummeted by 117.09% to -$3.6 million in 2021, then surged by 3,248.42% to $113.3 million in 2022, then tumbled by 146.57% to -$52.8 million in 2023, then surged by 93.87% to -$3.2 million in 2024.